Oncolytic Viruses Derived from the γ34.5-Deleted Herpes Simplex Virus Recombinant R3616 Encode a Truncated UL3 Protein

Molecular Therapy

Volumn 13, Issue 5, 2006, Pages 891-898

  Dambach, Megan J ^a   Trecki, Jordan ^a   Martin, Natalia ^a   Markovitz, Nancy S ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

cancer vaccine; DNA mutational analysis; gene therapy; genetic stability; genotypic characterization; herpes simplex virus 1 ICP34.5 protein; herpes simplex virus 1 UL3 protein; neurotoxicity; nonsense mutation; oncolytic virus

Indexed keywords

CANCER VACCINE; ONCOLYTIC VIRUS; UL3 PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR; GAMMA 34.5 PROTEIN, HUMAN HERPESVIRUS 1; RECOMBINANT DNA; UL3 PROTEIN, HUMAN HERPESVIRUS 1; VIRUS DNA;

ANIMAL CELL; ARTICLE; GENE DELETION; GENETIC CODE; GENETIC STABILITY; HERPES SIMPLEX VIRUS 1; MALIGNANT NEOPLASTIC DISEASE; MUTATIONAL ANALYSIS; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CHARACTERIZATION; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; CERCOPITHECUS; CHEMISTRY; COMPARATIVE STUDY; CONSENSUS SEQUENCE; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KERATINOCYTE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; RABBIT; SEQUENCE HOMOLOGY; STOP CODON; VERO CELL; VIROLOGY; VIRUS GENE;

ANIMALIA; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; CODON, NONSENSE; CONSENSUS SEQUENCE; DNA, RECOMBINANT; DNA, VIRAL; GENE DELETION; GENE EXPRESSION REGULATION, VIRAL; GENES, VIRAL; HERPESVIRUS 1, HUMAN; HUMANS; KERATINOCYTES; MOLECULAR SEQUENCE DATA; ONCOLYTIC VIRUSES; RABBITS; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; VERO CELLS; VIRAL PROTEINS;

EID: 33645874763     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.02.006     Document Type: Article

References (47)

1. Glorioso J.C., and Fink D.J. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu. Rev. Microbiol. 58 (2004) 253-271
2. Kasuya H., Takeda S., Nomoto S., and Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 12 (2005) 725-736
3. Shah A.C., Benos D., Gillespie G.Y., and Markert J.M. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neuro-Oncol. 65 (2003) 203-226
4. + are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell-cultures. J. Virol. 68 (1994) 48-55
5. Chou J., Kern E.R., Whitley R.J., and Roizman B. Mapping of herpes simplex virus-1 neurovirulence to γ134.5, a gene nonessential for growth in culture. Science 250 (1990) 1262-1266
6. + between immediate early gene-1 and the a sequence. J. Gen. Virol. 72 (1991) 631-639
7. Mohr I., et al. A herpes simplex virus type 1 γ34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. 75 (2001) 5189-5196
8. Robertson L.M., MacLean A.R., and Brown S.M. Peripheral replication and latency reactivation kinetics of the non-neurovirulent herpes-simplex virus type-1 variant-1716. J. Gen. Virol. 73 (1992) 967-970
9. 134.5 deletion mutants in rodent models. J. Clin. Invest. 91 (1993) 2837-2843
10. McKay E.M., McVey B., Marsden H.S., Brown S.M., and MacLean A.R. The herpes-simplex virus type-1 strain-17 open reading frame RL1 encodes a polypeptide of apparent M(r) 37K equivalent to ICP34.5 of herpes-simplex virus type-1 strain-F. J. Gen. Virol. 74 (1993) 2493-2497
11. Roizman B., and Knipe D.M. Herpes simplex viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 2399-2457
12. Pyles R.B., Sawtell N.M., and Thompson R.L. Herpes-simplex virus type-1 dUTPase mutants are attenuated for neurovirulence, neuroinvasiveness, and reactivation from latency. J. Virol. 66 (1992) 6706-6713
13. Pyles R.B., and Thompson R.L. Evidence that the herpes-simplex virus type-1 uracil DNA glycosylase is required for efficient viral replication and latency in the murine nervous-system. J. Virol. 68 (1994) 4963-4972
14. McKie E.A., Brown S.M., MacLean A.R., and Graham D.I. Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy. Neuropathol. Appl. Neurobiol. 24 (1998) 367-372
15. Hunter W.D., et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73 (1999) 6319-6326
16. Thompson R.L., Devi-Rao G.V., Stevens J.G., and Wagner E.K. Rescue of a herpes-simplex virus type-1 neurovirulence function with a cloned DNA fragment. J. Virol. 55 (1985) 504-508
17. Varghese S., et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Ther. 12 (2001) 999-1010
18. Brown S.M., Harland J., MacLean A.R., Podlech J., and Clements J.B. Cell-type and cell state determine differential in-vitro growth of non-neurovirulent ICP34.5-negative herpes-simplex virus type-1 and type-2. J. Gen. Virol. 75 (1994) 2367-2377
19. McKie E.A., et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-Evaluation of a potentially effective clinical therapy. Br. J. Cancer 74 (1996) 745-752
20. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., and Martuza R.L. Attenuated multi-mutated herpes-simples virus-1 for the treatment of malignant gliomas. Nat. Med. 1 (1995) 938-943
21. Harrow S., Papanastassiou V., Brown S.M., Fraser M., and Rampling R. Phase 1 trial of herpes simplex virus, HSV1716, following injection into brain adjacent to tumour in patients with primary malignant glioma. Br. J. Cancer 86 (2002) S26-S27
22. Harrow S., et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11 (2004) 1648-1658
23. Varghese S., and Rabkin S.D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9 (2002) 967-978
24. Liu B.L., et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10 (2003) 292-303
25. Markert J.M., et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7 (2000) 867-874
26. -) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther. 9 (2002) 398-406
27. Rampling R., et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7 (2000) 859-866
28. Liu R., Martuza R.L., and Rabkin S.D. Intracarotid delivery of oncolytic HSV vector G47Δ to metastatic breast cancer in the brain. Gene Ther. 12 (2005) 647-654
29. Pyles R.B., Warnick R.E., Chalk C.L., Szanti B.E., and Parysek L.M. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8 (1997) 533-544
30. Kramm C.M., et al. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8 (1997) 2057-2068
31. Baines J.D., and Roizman B. The open reading frames UL3, UL4, UL10, and UL16 are dispensable for the replication of herpes simplex virus 1 in cell culture. J. Virol. 65 (1991) 938-944
32. McGeoch D.J., et al. The complete DNA-sequence of the long unique region in the genome of herpes-simplex virus type-1. J. Gen. Virol. 69 (1988) 1531-1574
33. Markovitz N.S., Filatov F., and Roizman B. The UL3 protein of herpes simplex virus 1 is translated predominantly from the second in-frame methionine codon and is subject to at least two posttranslational modifications. J. Virol. 73 (1999) 8010-8018
34. Markovitz N.S., and Roizman B. Small dense nuclear bodies are the site of localization of herpes simplex virus 1 UL3 and UL4 proteins and of ICP22 only when the latter protein is present. J. Virol. 74 (2000) 523-528
35. Mohr I., and Gluzman Y. A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 15 (1996) 4759-4766
36. Worrad D.M., and Caradonna S. The herpes-simplex virus type-2 UL3 open reading frame encodes a nuclear localizing phosphoprotein. Virology 195 (1993) 364-376
37. Dolan A., Jamieson F.E., Cunningham C., Barnett B.C., and McGeoch D.J. The genome sequence of herpes simplex virus type 2. J. Virol. 72 (1998) 2010-2021
38. Brown J. Effect of gene location on the evolutionary rate of amino acid substitutions in herpes simplex virus proteins. Virology 330 (2004) 209-220
39. Hwang Y.T., Liu B.Y., Hong C.Y., Shillitoe E.J., and Hwang C.B.C. Effects of exonuclease activity and nucleotide selectivity of the herpes simplex virus DNA polymerase on the fidelity of DNA replication in vivo. J. Virol. 73 (1999) 5326-5332
40. Barnes D.E., and Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu. Rev. Genet. 38 (2004) 445-476
41. Lasken R.S., and Goodman M.F. The biochemical basis of 5-bromouracil-induced mutagenesis: heteroduplex base mispairs involving bromouracil in G × C-A × T and A × T-G × C mutational pathways. J. Biol. Chem. 259 (1984) 11491-11495
42. Sargent R.G. Ribonucleotide reductase: a determinant of 5-bromodeoxyuridine mutagenesis in phage T4. Mol. Gen. Genet. 217 (1989) 13-19
43. Lindahl T., and Wood R.D. Quality control by DNA repair. Science 286 (1999) 1897-1905
44. Drake J.W., and Hwang C.B.C. On the mutation rate of herpes simplex virus type 1. Genetics 170 (2005) 969-970
45. Ejercito P.M., Kieff E.D., and Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J. Gen. Virol. 2 (1968) 357-364
46. Post L.E., and Roizman B. A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth. Cell 25 (1981) 227-232
47. Chou J., and Roizman B. The terminal a sequence of the herpes simplex virus genome contains the promoter of a gene located in the repeat sequences of the L component. J. Virol. 57 (1986) 629-637